

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

## **UPDATES OF FINANCIAL PERFORMANCE FOR THE SIX MONTHS ENDED 30 JUNE 2024**

This announcement is made by PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (“**2024 Interim Period**”) and other information currently available to the Board, it is expected that the Group will record an unaudited consolidated net loss of not more than approximately HK\$20 million for the 2024 Interim Period, as compared to the unaudited consolidated net loss of approximately HK\$37.7 million recorded for the corresponding period ended 30 June 2023. Such significant decrease in the unaudited consolidated net loss in 2024 Interim Period was mainly attributable to i) the reduction in the fair value loss of the biological assets related to the Group’s plantation segment since it had been fully impaired during the year ended 31 December 2023; and ii) the reduction in administrative expenses and selling and distribution expenses as a result of the cost control activities for the Group’s operation.

The Company is still in the process of finalising the interim results of the Group for the 2024 Interim Period. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available, including the unaudited consolidated management accounts of the Group for the 2024 Interim Period, which are yet to be finalised and have not been reviewed by the audit committee of the Board and are subject to adjustments. The actual interim results of the Group for the 2024 Interim Period may be different from the information disclosed in this announcement. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the 2024 Interim Period, which is expected to be published by the end of August 2024 in accordance with the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman and executive Director*

Hong Kong, 16 August 2024

*As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola, the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*